EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische Studie

Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes

Julio Rosenstock iD, Deborah A Robins, Kevin L Duffin, Jonathan M Wilson, Yanzhu Lin, Hiya Banerjee, Sarah Eyde, Christof Kazda iD, Manige Konig, Kieren J Mather iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.70022 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Julio Rosenstock und 9 weiteren Autor:innen. Beteiligte Einrichtung: Velocity Clinical Research at Medical City, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin Resistance, Insulin-Secreting Cells, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

These participant‐level exploratory analyses evaluated the effects of orforglipron, a once‐daily, orally administered non‐peptide glucagon‐like peptide‐1 receptor agonist, versus dulaglutide and placebo, on β‐cell function and insulin sensitivity biomarkers. Materials and Methods Participants ( N = 378) in this 26‐week phase 2 study with inadequately controlled type 2 diabetes (T2D) were randomly assigned to orforglipron (3, 12, 24, 36, or 45 mg), dulaglutide (1.5 mg), or placebo. Treatment effects on β‐cell function and insulin sensitivity markers were assessed, including homeostatic model assessment indices of β‐cell function and insulin resistance (HOMA‐B and HOMA‐IR, respectively); fasting C‐peptide, insulin, serum glucose, and glucagon; adiponectin; insulin‐like growth factor binding protein 2; proinsulin; and the proinsulin/insulin ratio.

Results

Orforglipron doses of 12 mg and higher were associated with improved β‐cell function and insulin sensitivity. HOMA‐B increased up to 123% (C‐peptide) and 132% (insulin) with orforglipron doses of 12 mg and higher from baseline to week 4 before stabilising. HOMA‐B increases were greater with all orforglipron doses than with dulaglutide. Additional β‐cell function biomarkers, such as fasting proinsulin and the proinsulin/insulin ratio, also improved with orforglipron doses of 12 mg and higher compared with baseline and to a greater extent than seen with dulaglutide. HOMA‐IR values decreased up to 16% (C‐peptide) and 23% (insulin) with orforglipron by week 26. Reductions in HOMA‐IR (insulin) were significant versus baseline only for the highest dose. IGFBP‐2 and adiponectin, corollary biomarkers of insulin sensitivity, were generally improved with orforglipron.

Conclusions

Increased HOMA‐B and improved metabolic biomarkers suggest that treatment with the orally administered non‐peptide GLP‐1 receptor agonist orforglipron enhanced pancreatic β‐cell function and insulin sensitivity in patients with T2D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Insulin ResistanceInsulin-Secreting CellsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsHumansMaleFemaleMiddle AgedGlucagon-Like PeptidesBiomarkersImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsBlood GlucoseC-PeptideAdministration, OralAgedInsulinDouble-Blind MethodAdiponectinAdultOxadiazolesFluorine Compounds

Stichwörter der Autor:innen

GLP‐1anti‐diabetic drugbeta cell functionglycaemic controlinsulin resistanceinsulin secretion

Substanzen

Glucagon-Like PeptidesGlucagon-Like Peptide-1 Receptor AgonistsBiomarkersImmunoglobulin Fc FragmentsdulaglutideHypoglycemic AgentsRecombinant Fusion ProteinsBlood GlucoseC-PeptideInsulin

Autor:innen und Institutionen

  • Velocity Clinical Research at Medical City, Dallas, Texas, USA.
  • Eli Lilly and Company, Indianapolis, Indiana, USA.

ORCID-Profile: Julio Rosenstock, Christof Kazda, Kieren J Mather

Förderung

  • Eli Lilly and Company

Zitieren

APA

Rosenstock, J., Robins, D. A., Duffin, K. L., Wilson, J. M., Lin, Y., Banerjee, H., Eyde, S., Kazda, C., Konig, M., & Mather, K. J. (2025). Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70022

Vancouver

Rosenstock J, Robins DA, Duffin KL, Wilson JM, Lin Y, Banerjee H, et al. Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70022

BibTeX
@article{Rosenstock2025,
  author = {Rosenstock, Julio and Robins, Deborah A and Duffin, Kevin L and Wilson, Jonathan M and Lin, Yanzhu and Banerjee, Hiya and Eyde, Sarah and Kazda, Christof and Konig, Manige and Mather, Kieren J},
  title = {Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.70022}
}
Kostenlos starten →